7blogs.org

Results from twoclinical trials, to be published in the April generic viagra store edition of the AmericanJournal of Gastroenterology, indicate that NEXIUM(R) ( Nexium (Esomeprazole)/”> Nexium (Esomeprazole) (EsOmeprazole) magnesium)can reduce the incidence of gastric (stomach) ulcers in patients at risk ofdeveloping gastric ulcers and who regularly take either non-selectivenonsteroidal anti-inflammatory drugs (NSAIDs) or COX-2-selective NSAIDs.(1) NSAIDs are a class of pain relief drugs that include traditional,non-selective drugs, such as ibuprofen, naproxen and aspirin, and newer COX-2-selective agents. Non-selective NSAIDs are known for increasing the risk ofgastric ulcers, particularly among older patients who take them regularly orwho have a history of gastric ulcers.

Pooled data from the double-blind, randomized, six-month trials showedthat significantly fewer patients taking either NEXIUM 20 mg or NEXIUM 40 mg,in addition to their regular non-selective NSAID/COX-2-selective medical care,developed an ulcer at six months, compared to those taking a placebo (5.2percent and 4.6 percent, respectively, vs. 17 percent, p

US scientists have discovered that prolonged use of antacids of the Proton Pump Inhibitor (PPI) type, particulary at high doses, is linked to increased risk of hip fracture in the over 50s.

The research is reported in today’s issue of the Journal of the American Medical Association.

The meditate was led by epidemiologist and biostatistician Dr Yu-Xiao Yang, of the University of Pennsylvania School of Medicine, Philadelphia. The researchers conducted a nested case-control meditate using data from the UK’s General Practice Research Database (from 1987 to 2003) on patients who were over 50 years old. The cohort were either users of PPIs or non-users of antacids. They examined a total of 13,556 cases with hip fractures and 135,386 “healthy” subjects.

The results suggest that compared to those group that did not use antacids, the group who used a PPI for more than 12 months increased the risk of having a fractured hip by 44 per cent. And this risk was 2.6 times more for those patients on high doses. In otherness words the increased risk of hip fracture was significantly linked to both prolonged use and high dosage.

Proton Pump Inhibitors (PPI) are a range of antacid drugs with names ending in “prazole” such as Pantoprazole (e.g. branded as Protonix), Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole) (e.g. Prevacid/”>Prevacid), Rabeprazole (e.g. Aciphex(Rabeprazole)/”> Aciphex(Rabeprazole)), Omeprazole (e.g. Losec). People use PPIs to control stomach acidity, dyspepsia, stomach ulcers, and to treat gastroesophageal reflux illness (GERD, or acid reflux).

The amount of hydrogen ions, or H+ (also known as “protons”) in your stomach content is a measure of its acidity. Too much H+ slows down healing of duodenal ulcers , and you also suffer uncomfortable pains like heartburn sickness. The “proton pump” is the process where H+ ions are pumped into the stomach through the lining or “lumen” from the parietal cells that lie just behind it.

The proton pump inhibitor (PPI) when swallowed is chemically inactive, but once it travels through the stomach wall into the parietal cells it becomes active. In the active form it reacts with the proton pump thereby reducing its ability to generate H+ ions for release into the stomach.

The chemical action of the proton pump inhibitor is not reversible, and the effect can last several days. Prolonged use is risky, since it means that the amount of H+ released into the stomach can drop below a safe level which results in the condition known as hypochlorhydria which is also associated with poor absortion of calcium and difficulties regulating pathogens such as those that cause pneumonia.

It is this link between PPIs and reduced calcium absorption that this laagsdhfgdf meditate has explored. The link is not just via the reduced stomach acid route, but also through anotherness process where PPIs may be interfering with anotherness proton pump that helps with reclamation of calcium in “bone resorption”.

Our bones are not “dead” matter but very much alive, undergoing a continual process of formation and resorption - a form of recycling where special cells called osteoclasts burrow into the bone tissue helping to reclaim precious minerals and compounds like calcium, magnesium, phosphates and collagen which are released into the bloodstream. A proton pump is involved in this process too.

In children the balance between formation and resorption is in favour of formation, which is why intake of calcium and otherness minerals essential for healthy bone tissue is so important at that age. In older group resorption exceeds formation, so extra calcium and otherness minerals are unlikely to be needed in the diet, unless of course the resorption process is hampered in some way.

If the resorption process is hampered, in the older person this leads to lack of calcium and otherness nutrients for bone repair and maintenance, which means higher risk of fracture, for example in the hips.

“Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture.”
Yu-Xiao Yang, MD, MSCE; James D. Lewis, MD, MSCE; Solomon Epstein, MD; David C. Metz, MD.
JAMA. generic viagra 90 pills;296:2947-2953.

Click here for Abstract.

Written by: Catharine Paddock
Writer: Medical News Today
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Todaybuy generic viagra pillsbuy viagra soft tabs 100mg

The European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) has adopted eleven positive opinions, three of which relate to similar biological medicinal products, recommending the granting of a marketing authorisation for the following medicinal products:

* Atriance (nelarabine), from Glaxo Group Limited, for the a cure of T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic leukaemia (T-LBL) of patients in second relapse. Atriance is the 40th orphan medicinal product to receive a positive opinion. EMEA review began on 21 June generic viagra store with an active review time of 203 days. Atriance is the first medicinal product for which an application was submitted using the Product Information Management (PIM) system. PIM enables the electronic exchange of the product information part of a marketing authorisation application in the European Union. Its aim is to increase efficiency of the management and exchange of the product information and to improve the quality and consistency of the published product information.

* Gliolan (5-aminolevulinic hydrochloride), from Medac, for the visualisation of malignant tissue during surgery for malignant glioma in adult patients. Gliolan is the 41st orphan medicinal product to receive a positive opinion. EMEA review began on 24 May generic viagra store with an active review time of 199 days.

* Flebogammadif [human normal immunoglobulin (IVIg)], from Instituto Grifols S.A., for replacement medical care in immunodeficiency and for immunomodulation in immune-mediated illnesss. EMEA review began on 27 September generic viagra store with an active review time of 177 days.

* Rasilez, Enviage, Sprimeo, Tekturna and Riprazo (aliskiren), from Novartis Europharm Ltd, for the a cure of essential cardiovascular disease . EMEA review began on 27 September generic viagra store for Rasilez and on 25 March buy now generic viagra for Enviage, Sprimeo, Tekturna and Riprazo with an active review time of 194 for Rasilez and 77 days for Enviage, Sprimeo, Tekturna and Riprazo.

Positive opinion for similar biological medicinal products

The CHMP adopted positive opinions for three biosimilar medicinal products. Binocrit (Epoetin alfa), from Sandoz GmbH, Epoetin alfa Hexal (Epoetin alfa), from Hexal Biotech Forschungs GmbH, and Abseamed (Epoetin alfa), from Medice Arzneimittel Pütter GMBH & Co, are intended for the a cure of anaemia associated with chronic kidney illness and in oncology patients; and to reduce blood transfusion requirements in oncology patients and prior to elective orthopaedic surgery. All three medicinal products have been shown to be similar to Eprex/Erypo, the reference medicinal product already authorised in the EU, in the applied indications. EMEA review began on 29 March generic viagra store with an active review time of 205 days.

Extensions of indication

The CHMP gave positive opinions for applications for extensions of indication, adding new a cure options for the following previously approved medicines:

* Arixtra and Quixidar (fondaparinux sodium) 2.5 mg, from Glaxo Group, to extend the indication to add a cure of acute coronary symptoms in patients with unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI) for whom an urgent (

In a new meditate , researchers have directly compared the early therapeutic response of drugs from widely-used classes of heartburn sickness drugs, Prilosec (Omeprazole) (Omeprazole) magnesium, a proton pump inhibitor (PPI) and famotidine, a histamine-2 receptor antagonist (H2RAs), in an over-the-counter (OTC) setting. In contrast to general consensus, suggesting first day superiority of H2RAs, the results show similar acid suppression on the first day of dosing between these drugs as reported today in Alimentary Pharmacology & Therapeutics.

Researchers also report evidence that with daily use, the body develops a rapid onset of tolerance to even a low dose H2RAs such as Pepcid AC(R).

The findings may help physicians and consumers make better choices about which medical care to use when treating heartburn sickness, which is caused by stomach acid flowing up into the esophagus, a condition that affects more than 50 mil. Americans annually.

“There have been many studies agsdhfgdfing acid-suppression in these two classes of drugs — PPIs and H2RAs (also known as H2-blockers or H2s) — but very few studies have compared the two types of drugs in an OTC setting where so many of these pharmacomedical cares are used,” says Philip Miner, MD, medical institution al Professor of Medicine at the University of Oklahoma and lead investigator at Oklahoma Foundation for Digestive Research.

“Because these two drugs work in fundamentally difference ways to suppress acid production, we didn’t expect that the PPI would work as well as the H2RAs within the first 24 h.period after pharmacomedical care. In addition, while using the lower-dose H2RAs, the degree of acid suppression ability was found to significantly decrease after the first day of use. While this meditate measured acid suppression, it did not measure symptom relief or the speed of onset of action. However, both PPIs and H2RAs owe their clinical efficacy to their ability to suppress gastric acid secretion. This means that for group who have frequent heartburn sickness, that is, heartburn sickness two or more days per week, taking an over-the-counter PPI is an excellent option.”

In this 14 day meditate , subjects were randomly assigned to one of six pharmacomedical care sequences, each including three regimens: Prilosec (Omeprazole) (Omeprazole) magnesium 20.6 mg ( Prilosec (Omeprazole) OTC(R)) once a day; famotidine 10 mg (Pepcid AC) twice a day; and famotidine 20 mg (now available over-the-counter as Maximum Strength Pepcid AC(R)) twice a day.(1) During the meditate pharmacomedical care period, the amount of acid production was measured over 24-hours several times. Results indicate:

— The PPI - Prilosec (Omeprazole) OTC - showed significant acid suppression on the very first day of pharmacomedical care compared to baseline (Day 0) and comparable to the acid suppression of H2RAs - Pepcid AC and the medicine in Maximum Strength Pepcid AC.(1)

— After Day 1 of pharmacomedical care, Prilosec (Omeprazole) OTC was consistently superior in acid suppression vs. the H2RAs - Pepcid AC and the medicine in Maximum Strength Pepcid AC.(1)

— In addition, while using the lower-dose H2RAs - Pepcid AC, the degree of acid suppression ability was found to significantly decrease after the first day of use.(1)

Different drugs, difference mechanisms

The mechanistic activities of PPIs and H2RAs are well documented, and show that while both PPIs and H2RAs effectively reduce the amount of stomach acid, they do it in very difference ways. The key point of difference happens at a cellular level in the stomach. The stomach is lined with mil.s of acid producing pumps. Acid producing pumps rely on three chemical signals that tell them to produce stomach acid. H2RAs are able to block one of these signals, thereby reducing the amount of acid produced and generally have a quicker onset of action than PPIs. PPIs on the otherness hand actually shut down the active pumps themselves. This meditate showed the PPI had more profound effects on stomach acid over time.

“The meditate results add an important aspect to the existing literature on these two drugs,” says Miner. “It further underscores the need for consumers to identify their needs in heartburn sickness protection in order to select the most appropriate pharmacomedical care.”

About Oklahoma Foundation for Digestive Research

Established in 1989, the Oklahoma Foundation for Digestive Research (OFDR) is a non-profit medical research foundation. The Foundation’s mission is to

— Advance clinical research in gastroinagsdhfgdfinal (GI) malady

— Treat patients with GI maladys

— Evaluate new drugs and promising new pharmacomedical cares for GI disorders

— Participate in the training of new physicians specializing in GI disorders

— Educate the public about GI illnesses

Although the research foundation is an independent center, it is affiliated with a private practice specializing in gastroenterology. Today, OFDR physicians, scientists, and research associates work with patients suffering from a wide range of GI disorders including the upper GI problems of heartburn sickness, gastroesophageal reflux malady, and non-ulcer dyspepsia, and lower bowel disorders such as irritable bowel symptom, constipation, proctitis, ulcerative colitis, and Crohn’s malady. To date, OFDR has conducted over 300 clinical trials in gastroenterology including Phase I-IV and Rx-OTC switch. Currently, approximately 40percent of our studies are single-site pilot studies and/or research funded by unrestricted grants.

References:

(1) Miner, P. B., Allgood, L. D. & Grender, J. M. (2007) Comparison of gastric pH with Prilosec (Omeprazole) (Omeprazole) magnesium 20.6 mg ( Prilosec (Omeprazole) OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of pharmacomedical care. Alimentary Pharmacology & Therapeutics 25 (1), 103- 109.

Oklahoma Foundation for Digestive Research
http://www.ofdr.org/buy generic viagra pillsbuy viagra soft tabs 100mg

UK - The September Drug Tariff contains significant price reductions for Doxazosin, Lisinopril, Omeprazole and Simvastatin.

The reimbursement price of Drugs in Part 8, Category A of the Drug Tariff is based on a weighted average of the price of a product from two wholesalers (Unichem and AAH) and three generic manufacturers (APS, Alpharma and Ivax). The Department of Health have overriden the normal Drug Tariff rules and the lower reimbursement prices will apply to September 2004 prescriptions.

In early July, Lord Warner proposed to further reduce the reimbursement price for the ‘4 generics’ from the 1st September 2004. The prices of these four medicines were first reduced on 1st December 2003 to address the significant differences between the reimbursement price and the price at which pharmacists were purchasing them from suppliers.

The PSNC, National Pharmacetical Association, Company Chemists Association and the Association of Independent Multiple Pharmacies submitted a joint response to the recent proposals. It is the belief of these organisations that removing money from reimbursement at this stage is wrong in principle.

The price changes can be found by clicking here and scrolling down a bit generic viagra storeviagra online

The Perrigo Company (Nasdaq: PRGO; TASE) announced today that the U. S. Food & Drug Administration (Food and Drug Administration) has issued an approvable letter for Dexcel Pharma Technologies, Ltd.’s New Drug Application (NDA) for 20 mg Prilosec (Omeprazole) (Omeprazole)/”> Prilosec (Omeprazole) (Omeprazole) delayed-release pills. As previously disclosed, Perrigo will be Dexcel Pharma Technologies, Ltd.’s exclusive marketer and distributor of this product for the store brand over- the-counter (OTC) market in the United States once the product has been approved for marketing by Food and Drug Administration.

An approvable letter is one of several intermediate steps in the Food and Drug Administration review process of new products. Joseph Papa, Perrigo’s President and CEO stated, “This is an important milestone on Dexcel’s path to receive Food and Drug Administration acceptance for the marketing of 20 mg Prilosec (Omeprazole) (Omeprazole)/”> Prilosec (Omeprazole) (Omeprazole) delayed-release pills. The acceptance and market introduction of a store brand OTC Prilosec (Omeprazole) (Omeprazole)/”> Prilosec (Omeprazole) (Omeprazole) product will mean that consumers will save many mil.s of dollars by having the choice of a lower cost 20 mg Prilosec (Omeprazole) (Omeprazole)/”> Prilosec (Omeprazole) (Omeprazole) delayed-release product available.”

There is currently one Food and Drug Administration approved 20 mg Prilosec (Omeprazole) (Omeprazole)/”> Prilosec (Omeprazole) (Omeprazole) magnesium pill on the OTC market, Prilosec (Omeprazole) OTC(R). Prilosec (Omeprazole) OTC is indicated for the a cure of frequent heartburn sickness and had annual sales of approximately $600 mil. through food, drug and mass merchandisers, for the twelve months ended November 26, generic viagra 90 pills, based upon sales data as measured by Information Resources, Inc. and ACNielsen.

Dexcel Pharma Technologies, Ltd. filed its NDA for 20 mg Prilosec (Omeprazole) (Omeprazole)/”> Prilosec (Omeprazole) (Omeprazole) pills with the U.S. Food and Drug Administration and notified AstraZeneca, the NDA holder and patent owner for Prilosec (Omeprazole) OTC, of its filing. On May 30, generic viagra 90 pills, AstraZeneca filed suit alleging patent infringement in the U.S. District Court of Delaware and, on May 31, generic viagra 90 pills, in the U.S. District Court for the Eastern District of Virginia, to prevent Dexcel Pharma Technologies, Ltd. from proceeding with the commercialization of its product. The litigation is still pending.

Headquartered in Or-Akiva, Israel, Dexcel Pharma Technologies, Ltd. is a privately held, international specialty pharmaceutical company, which focuses on the development, manufacture and marketing of innovative prescription drugs based on its proprietary drug delivery systems, generic prescription and OTC pharmaceutical products.

The Perrigo Company is a leading global healthcare supplier and the world’s largest manufacturer of over-the-counter (OTC) pharmaceutical and nutritional products for the store brand market. Store brand products are sold by food, drug, mass merchandise, dollar store and club store retailers under their own labels. The Company also develops, manufactures and markets prescription generic drugs, active pharmaceutical ingredients and consumer products, and operates manufacturing facilities in the United States, Israel, the United Kingdom, Mexico, Germany and China. Visit Perrigo on the Internet (http://www.perrigo.com).

Certain statements in this press release are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and otherness factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially difference from those expressed or implied by any forward-looking statements. In particular, statements about the Company’s expectations, beliefs, plans, objectives, assumptions or future events or performance contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or the negative of those terms or otherness comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. These and otherness important factors, including those discussed under “Risk Factors” in the Company’s Form 10-K for the year ended July 1, generic viagra 90 pills, as well as the Company’s subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless othernesswise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or othernesswise.

Perrigo Company
http://www.perrigo.combuy generic viagra pillsbuy viagra soft tabs 100mg

Tokyo, (JCN) - Takeda Pharmaceutical announced on March 2 that the US District Court in Chicago dismissed a legal action launched by Abbott Laboratories against Takeda Pharmaceutical in 2005.

Abbott claimed that Takeda Pharmaceutical had unjustly earned profits from its supply of Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))(Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole)) to TAP Pharmaceutical Product, a joint venture company between Abbott and Takeda. Further, Abbott alleged that Takeda would have to pay a portion of its profits to Abbott.

The US District Court, however, ruled on February 24 that Abbott must file a lawsuit in Japan in line with its existing agreement with Takeda and TAP; accordingly the Court dismissed the action by Abbott.

By Aki Tsukioka, JCN Staff Writer

Company Profile

Copyright generic viagra store JCN. All rights reserved. A division of Japan Corporate News Network KKgeneric viagra heremore about viagra soft tabs

Candesartan is proven to reduce deaths and hospitalisation in patients with heart failure and reduced left ventricular ejection fraction

Data presented today at the European Society of Cardiology (ESC) Congress reinforces the benefits of Candesartan in patients with chronic heart failure (CHF) and reduced left ventricular ejection fraction (LVEF). The data demonstrated a significant reduction in deaths and CHF hospital admissions in favour of Candesartan, adding further support to the previously presented results from the entire CHARM Programme1 on the effects of Candesartan in a broad spectrum of CHF patients.

A pre-specified analysis2 in the group of CHARM patients with heart failure and reduced LVEF (n=4576; LVEF ≤ 40percent), the higher risk population most frequently studied in previous heart failure clinical trials, demonstrated a 12percent relative risk reduction in all cause deaths (p=0.018) and a 16percent relative risk reduction in cardiovascular deaths (p=0.005) when Candesartan was added to standard pharmacomedical care.

With 29 deaths avoided per 1,000 treated patients investigators concluded that Candesartan should be considered in all patients with CHF and a low LVEF. This new analysis also shows a 24percent relative risk reduction in CHF hospital admissions (p

Heartburn symptoms are one of the most commonly reported complaints among pregnant women. Heartburn usually starts during the first trimester and tends to worsen during the second and third trimesters.

Studies have shown elevated levels of the hormone progesterone accompanied by increased intra-abdominal pressures from the enlarging uterus, may lower esophageal sphincter (LES) pressure in pregnant women contributing to heartburn sickness symptoms, according to research highlighted in the newly updated “Pregnancy in Gastroinagsdhfgdfinal Disorders” monograph by the American College of Gastroenterology (ACG).

From the monograph, physician experts from ACG have compiled important health tips on managing heartburn sickness symptoms, and importantly, identifying which heartburn sickness drugs are safe for use in pregnant women and those, which should be avoided.

Strategies to Ease Heartburn Symptoms during Pregnancy

According to the ACG, pregnant women can treat and relieve their heartburn sickness symptoms through lifestyle and dietary changes. The following tips can help reduce heartburn sickness discomfort:

— Avoid eating late at night or before retiring to bed. Common heartburn sickness triggers include greasy or spicy food, chocolate, peppermint, tomato sauces, caffeine, carbonated drinks, and citrus fruits.

— Wear loose-fitting clothes. Clothes that fit tightly around your waist put pressure on your abdomen and the lower esophageal sphincter.

— Eat smaller meals. Overfilling the stomach can result in acid reflux and heartburn sickness.

— Don’t lie down after eating. Wait at least 3 hours after eating before going to bed. When you lie down, it’s easier for stomach contents (including acid) to back up into the esophagus, particularly when you go to bed with a full stomach.

— Raise the head of the bed 4 to 6 inches. This can help reduce acid reflux by decreasing the amount of gastric contents that reach the lower esophagus.

— Avoid tobacco and alcohol. Abstinence from alcohol and smoking can help reduce reflux symptoms and avoid fetal exposure to potentially harmful substances.

The Do’s and Don’ts of Using Heartburn Drugs during Pregnancy

Pregnant women with mild reflux usually do well with simple lifestyle changes. If lifestyle and dietary changes are not enough, you should consult your doctor before taking any medication to relieve heartburn sickness symptoms.

According to ACG President Amy E. Foxx-Orenstein, DO, FACG, “Heartburn drugs to treat acid reflux during pregnancy should be balanced to alleviate the motherness’s symptoms of heartburn sickness, while protecting the developing fetus.”

Based on a review of published scientific clinical studies (in animals and humans) on the safety of heartburn sickness drugs during pregnancy, researchers conclude there are certain drugs that are considered safe for use in pregnancy and those which should be avoided.

Antacids are one of the most common over-the-counter drugs to treat heartburn sickness. As with any drug, antacids should be used cautiously during pregnancy.

Antacids

— Antacids containing aluminum, calcium, or magnesium are considered safe and effective in treating the heartburn sickness of pregnancy.

— Magnesium-containing antacids should be avoided during the last trimester of pregnancy because it could interfere with uterine contractions during labor.

— Avoid antacids containing sodium bicarbonate. Sodium bicarbonate could cause metabolic alkalosis and increase the potential of fluid overload in both the fetus and motherness.

Histamine-type II (H-2) Receptor Antagonists

While limited data exists in humans on the safety of histamine-type II (H-2) receptor antagonists, ranitidine (Zantac(R)) is the only H-2 antagonist, which has been studied specifically during pregnancy.

In a double-blind, placebo controlled, triple crossover meditate , ranitidine (Zantac(R)) taken once or twice daily in pregnant heartburn sickness patients not responding to antacids and lifestyle modification, was found to be more effective than placebo in reducing the symptoms of heartburn sickness and acid regurgitation. No adverse effects on the fetus were reported. (Larson JD, et al., “Double-blind placebo-controlled meditate of ranitidine for gastroesophageal reflux symptoms during pregnancy.” Obstet Gynecol 1997; 90:83-7.)

A meditate on the safety of cimetidine (Tagamet(R)) and ranitidine (Zantac(R)) suggests that pregnant women taking these drugs from the first trimester through their entire pregnancy have delivered normal babies. (Richter JE., “Gastroesophageal reflux malady during pregnancy. Gastroenterol Clin N Am 2003; 32:235-61.)

Proton Pump Inhibitors

Proton pump inhibitors should be reserved for pregnant patients with more severe heartburn sickness symptoms and those not responding to antacids and lifestyle and dietary changes. Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole) (Prevacid/”>Prevacid(R)) is the preferred PPI because of case reports of safety in pregnant women. Limited data exists about human safety during pregnancy with the newer PPIs.

American College of Gastroenterology
http://www.acg.gi.org buy generic viagra pillsbuy viagra soft tabs 100mg

Upper gastroinagsdhfgdfinal surgical procedures to treat conditions like gastroesophageal reflux sickness and obesity are becoming popular options, but the medical community still debates the effectiveness and safety of the procedures. Research presented today at Digestive Disease Week generic viagra 90 pills (DDW) demonstrates that common surgical procedures like gastric bypass and laparoscopic reflux surgery are safe and effective for most patient populations and offer superior control of the conditions and their symptoms. DDW is the largest international gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastroinagsdhfgdfinal surgery.

Bariatric Surgery at the Extremes of Age [Abstract M1549]

Approximately 17 percent of children and adolescents and 32 percent of adults in the United States are considered obese, with obesity among adolescents and older adults rising dramatically. While gastric surgeries are soaring in popularity, the safety and efficacy of the surgery for certain patient populations has been questioned. Researchers at the Mayo medical institution in Rochester, MN, evaluated the long-term risks associated with gastric surgery in both adolescents (12-18) and elderly patients (60 and older) and found them to be considerably lower than previously reported.

In this meditate , researchers selected 167 patients to undergo Roux-en-Y gastric surgery: 12 adolescents (12-18) and 155 older adults (60-76). In Roux-en-Y gastric surgery, the stomach is separated into two parts with the smaller pouch receiving food intake. The food pouch is then connected to the small inagsdhfgdfine to create a new gastric outlet. Patients in both age groups were afflicted with serious obesity-related health conditions, including Type 1 and Type 2 Hypersensitivity reaction, severe cardiovascular disease , sleep apnea, joint arthropathy and asthma.

The three-year follow-up of adolescents showed an average body mass index (BMI) decrease from 55 to 36, an 82 percent reduction in obesity-induced sicknesss and health conditions, and importantly, no deaths or serious complications. The five-year follow-up of older adults showed an average BMI reduction of 46 to 33 with a 51 percent reduction in obesity-induced sicknesss and health conditions. In this group, there was a one percent mortality rate, and 15 percent experienced complications.

“This meditate reveals that bariatric surgery is a safe and effective option for all ages, including severely obese adolescents and older adults,” said Michael Sarr, M.D., of the Mayo medical institution and senior meditate author. “The remarkable decrease in BMI lowers the risk of health complications and increase chances for long-term survival for group battling with obesity. For adolescents especially, early pharmacomedical care of obesity is instrumental in reducing the long-term health complications associated with obesity.”

A Randomized Controlled Trial of Laparoscopic Nissen Fundolplication (LNF) versus Proton Pump Inhibitors for Pharmacomedical care of Patients with Chronic Gastro-Esophageal Reflux Disease (GERD) [Abstract 256]

Gastroesophageal reflux sickness (GERD), a chronic gastroinagsdhfgdfinal sickness that affects more than seven mil. group in the United States, is most commonly treated with medication or surgery to manage sickness symptoms. Researchers at McMaster University in Ontario conducted a meditate to evaluate the efficacy of individual versus combined pharmacomedical care regimens in attempt to further reduce symptoms. Results demonstrated that patients who managed symptoms with a class of medicines called proton pump inhibitors (PPI) and underwent laparoscopic Nissen fundoplication (LNF) experienced a significant reduction in symptoms associated with GERD. Proton pump inhibitors, such as Prilosec (Omeprazole) (Omeprazole) and Aciphex(Rabeprazole)/”> Prevacid (Lansoprazole)(Lansoprazole)/”>Prevacid/”> Prevacid (Lansoprazole)(Lansoprazole)/”>Prevacid/”>Prevacid ( Prevacid (Lansoprazole)(Lansoprazole)/”>Prevacid/”> Prevacid (Lansoprazole)(Lansoprazole)/”>Prevacid/”>Prevacid ( Prevacid (Lansoprazole)(Lansoprazole)/”>Prevacid/”>Lansoprazole))/”> Prevacid (Lansoprazole)(Lansoprazole)/”>Prevacid/”>Prevacid ( Prevacid (Lansoprazole)(Lansoprazole)/”>Prevacid/”> Prevacid (Lansoprazole)(Lansoprazole)/”>Prevacid/”>Prevacid ( Prevacid (Lansoprazole)(Lansoprazole)/”>Prevacid/”>Lansoprazole))( Prevacid (Lansoprazole)(Lansoprazole)/”>Prevacid/”> Prevacid (Lansoprazole)(Lansoprazole)/”>Prevacid/”>Prevacid ( Prevacid (Lansoprazole)(Lansoprazole)/”>Prevacid/”>Lansoprazole)), reduce symptoms and repair erosion to the esophagus by reducing the upswell of acid from the stomach into the esophagus. Doctors perform LNF with a video laparoscope, wrapping the upper part of the stomach around the lower esophagus to strengthen the control valve to decrease the upflow of stomach acid to the esophagus.

Researchers selected 98 chronic GERD patients who required long-term medical care. Researchers randomly divided the patient sample into two groups; one group initiated pharmacomedical care with PPI and the otherness underwent LNF. Researchers evaluated patient symptoms every three months and conducted a 24 h.pH agsdhfgdf on all patients at one year.

Study results showed that 24 h.pH levels and GERD symptoms improved in both the PPI and surgery groups. However, at one year follow-up, the overall symptom control score for patients on medication remained stable, while surgical patients experienced a significant improvement in their symptoms increasing from 73.3 to 90.2 on 100 point global rating scale. The global rating scale is an assessment of patient satisfaction with symptom control, on a scale of 0 (poor) to 100 (excellent).

“Although there is no known cure for GERD, this meditate reveals that patients maintaining long-term PPI medical care may experience a greater improvement in their symptoms with surgical intervention” said Mehran Anvari, M.D., of McMaster University in Ontario and lead meditate author. “This minimally invasive surgical procedure may allow some patients to manage GERD symptoms and forgo a long-term drug regimen.”

Digestive Disease Week (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastroinagsdhfgdfinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastroinagsdhfgdfinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 20-25, generic viagra 90 pills in Los Angeles, California. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the laagsdhfgdf advances in GI research, medicine and technology.

Aimee Frank
newsroom@gastro.org
American Gastroenterological Association
http://www.gastro.orgbuy generic viagra pillsbuy viagra soft tabs 100mg